Binding molecules specific for FcγRIIA and uses thereof
The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a binding molecule that comprises:
(i) a heavy chain variable (VH) region comprising a VH-complementarity determining region (CDR)1 comprising SEQ ID NO: 29, VH-CDR2 comprising SEQ ID NO: 19, and VH-CDR3 comprising SEQ ID NO: 30; and
(ii) a light chain variable (VL) region comprising a VL-CDR1 comprising SEQ ID NO: 22, VL-CDR2 comprising SEQ ID NO: 31, and VL-CDR3 comprising SEQ. ID NO: 32.
2. The nucleic acid molecule of claim 1 , operably linked to a regulatory sequence.
3. A vector comprising the nucleic acid molecule of claim 1 .
4. A host cell transformed with a nucleic acid molecule of claim 1 , or the vector of claim 3 .
5. The host cell of claim 4 , which is a mammalian host cell.
6. A composition comprising the nucleic acid molecule of claim 1 , the vector of claim 3 , or the host cell of claim 4 .
7. A method of making a binding molecule that specifically binds FcγRIIA, the method comprising culturing the host cell of claim 4 under suitable conditions for producing the binding molecule.
8. The method of claim 7 , further comprising isolating the binding molecule.
9. A kit comprising the nucleic acid molecule of claim 1 .